BBNX
HealthcareBeta Bionics, Inc. · Medical - Equipment & Services · $530M
What is Beta Bionics, Inc.?
Beta Bionics is a commercial-stage medical device company focused on improving life for people who require insulin therapy. Based in Irvine, California, the company centers its work on automated insulin delivery technology for diabetes management.
Beta Bionics designs and commercializes devices that automate insulin delivery for people with diabetes. Its lead product, the iLet Bionic Pancreas, is cleared for use in adults and children aged six and older with type 1 diabetes. The company generates revenue through device sales and is expanding its pipeline to address insulin-dependent type 2 diabetes and bihormonal therapy combining insulin and glucagon. Partnerships with Abbott Diabetes Care and Xeris Pharmaceuticals support its development roadmap.
Beta Bionics was incorporated in 2015 and is headquartered in Irvine, California.
- iLet Bionic Pancreas — automated insulin delivery for type 1 diabetes
- Patch Pump — tubeless, skin-adhering insulin pump in development
- Bihormonal iLet — combined automated insulin and glucagon delivery
- iLet for type 2 diabetes — expanding indication under development
- Abbott and Xeris partnerships — integrated CGM and glucagon formulation
Is BBNX a Good Stock to Buy?
UQS Score rates BBNX as Below Average overall, reflecting a mixed profile across the five quality pillars.
The Growth pillar stands out as the clearest bright spot for Beta Bionics, consistent with a company in early commercial expansion with a differentiated product in a large addressable market. The Risk pillar also registers as Good, suggesting the company's financial structure and operational risk profile are more manageable than many peers at a similar stage.
Both the Quality and Moat pillars rate as Weak, pointing to limited profitability and a competitive position that has yet to be firmly established. The Valuation pillar is Elevated, meaning the current price reflects considerable optimism about future execution.
Pro members can view the complete pillar breakdown and underlying financial metrics to assess whether BBNX fits their portfolio criteria. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BBNX pay dividends?
No — Beta Bionics, Inc. does not currently pay a dividend.
Beta Bionics does not currently pay a dividend. As a commercial-stage medical device company still investing heavily in product development and market expansion, capital is directed toward growth initiatives rather than shareholder distributions. Investors in BBNX are generally seeking capital appreciation tied to the company's clinical and commercial progress.
When does BBNX report earnings?
Beta Bionics reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a recently public, commercial-stage company, Beta Bionics' quarterly results are closely watched for revenue growth trends and progress toward reducing operating losses. Investors typically focus on device adoption rates and partnership milestones rather than near-term profitability.
For the most recent quarter's results and guidance, visit Beta Bionics' investor relations page directly.
BBNX Price History
-48.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Beta Bionics, Inc.?
Based on Beta Bionics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BBNX Long-term Outlook
The Strong Growth pillar suggests Beta Bionics is on a trajectory of meaningful revenue expansion, driven by increasing adoption of the iLet Bionic Pancreas and a broadening pipeline. However, the Weak Quality and Moat pillars indicate that translating top-line growth into durable profitability remains a key challenge. The Elevated Valuation pillar signals that the market has already priced in a significant portion of the growth story, leaving limited room for execution shortfalls. The Good Risk pillar provides some reassurance that near-term financial stability is not an immediate concern.
Growth drivers
- Expanding commercial adoption of the iLet Bionic Pancreas across age groups
- Pipeline progression into bihormonal therapy and type 2 diabetes indications
- Strategic partnerships with Abbott Diabetes Care and Xeris Pharmaceuticals
Key risks
- Elevated valuation leaves little margin for execution or reimbursement setbacks
- Weak Moat rating reflects competitive pressure from established insulin delivery players
- Path to profitability remains uncertain for a commercial-stage device company
BBNX vs Peers
Beta Bionics operates in the broader healthcare device and services landscape alongside a range of companies at different stages and specializations.
Concentra focuses on occupational health and urgent care services, operating in a very different segment of healthcare delivery than Beta Bionics' device-centered diabetes focus.
Park Dental Partners operates in dental practice management, representing a services-based healthcare model distinct from Beta Bionics' medical device commercialization approach.
Profusa develops implantable biosensor technology for continuous physiological monitoring, placing it closer to Beta Bionics in the digital health and chronic disease management space.
Frequently Asked Questions
What does Beta Bionics do?
Beta Bionics designs and commercializes automated insulin delivery systems for people with diabetes. Its flagship product, the iLet Bionic Pancreas, automates insulin dosing for type 1 diabetes patients aged six and older. The company is also developing next-generation devices including a tubeless patch pump and a bihormonal system combining insulin and glucagon.
Does BBNX pay dividends?
No, Beta Bionics does not pay a dividend. The company is in a commercial-stage growth phase and directs its capital toward product development, clinical programs, and market expansion rather than shareholder distributions.
When does BBNX report earnings?
Beta Bionics reports on a quarterly cadence, as is standard for US-listed public companies. For the exact timing of upcoming earnings releases, check the investor relations section of the Beta Bionics website directly.
Is BBNX a good stock to buy?
The UQS Score rates BBNX as Below Average overall. While the Growth pillar is Strong and the Risk pillar is Good, the Quality and Moat pillars are both Weak, and the Valuation pillar is Elevated. Whether BBNX suits a given investor depends on individual risk tolerance and time horizon. See the full pillar breakdown on UQS Score for a deeper view.
Is BBNX overvalued?
The UQS Valuation pillar for BBNX is rated Elevated, suggesting the current market price reflects substantial optimism about future growth. This does not mean the stock will decline, but it does indicate limited margin of safety if commercial execution falls short of expectations.
How does BBNX compare to its competitors?
Beta Bionics occupies a specialized niche in automated insulin delivery, differentiating it from broader healthcare services companies. Among the comparable names tracked on this platform, Profusa shares the closest thematic overlap in digital health and chronic disease monitoring. The UQS Score platform provides side-by-side pillar comparisons for Pro members.
What is BBNX's market cap bracket?
Beta Bionics is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded Beta Bionics?
Beta Bionics was founded by Ed Damiano, a biomedical engineer whose personal connection to type 1 diabetes — his son was diagnosed with the condition — motivated the development of the iLet Bionic Pancreas. The company was incorporated in 2015 and is based in Irvine, California.
Is BBNX a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates BBNX as Below Average. The Strong Growth pillar points to meaningful commercial momentum, but Weak Quality and Moat ratings suggest the company has not yet built the durable financial foundation typically associated with high-quality long-term holdings. Pro members can track how these pillar ratings evolve over time.
What is the main competitive advantage of Beta Bionics?
Beta Bionics' primary differentiation lies in the iLet Bionic Pancreas, which uses a simplified, algorithm-driven approach to insulin dosing that requires minimal user input. Partnerships with Abbott Diabetes Care for continuous glucose monitoring integration and Xeris Pharmaceuticals for glucagon formulation further support its technology ecosystem. However, the UQS Moat pillar currently rates this advantage as Weak relative to the broader competitive landscape.
What sector does BBNX belong to?
Beta Bionics operates in the Healthcare sector, specifically within the medical device segment focused on diabetes management technology. It sits at the intersection of hardware, software, and chronic disease care — a space that attracts both specialized device companies and larger diagnostics players.
Unlock Full BBNX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare BBNX side-by-side with sector peers
- ✓Track pillar rating changes over time
- ✓Screen for stocks with stronger Quality and Moat profiles
- ✓Get the complete analyst-style view in one dashboard
Pro Analysis
BBNX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 41.1 | 7.1 | 34.0 | 100.0 | 72.1 | 0.0 | +1.8 |
| May 10, 2026 | 39.3 | 0.0 | 34.0 | 100.0 | 72.1 | 0.0 | -1.8 |
| Apr 23, 2026 | 41.1 | 7.1 | 34.0 | 100.0 | 72.1 | 0.0 | +0.1 |
| Apr 2, 2026 | 41.0 | 7.1 | 34.0 | 100.0 | 71.6 | 0.0 | — |
BBNX — Pillar Breakdown
Quality
— 7.1/100 (25%)Beta Bionics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Beta Bionics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 72.1/100 (15%)Beta Bionics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Beta Bionics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 34/100 (25%)Beta Bionics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BBNX.
Score Composition
Financial Data
More Stock Analysis
How is the BBNX UQS Score Calculated?
The UQS (Unified Quality Score) for Beta Bionics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Beta Bionics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Beta Bionics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.